HOME > Investors > Press Releases
2011-10-13
ViroMed’s DNA Medicine(VM202) Receives Phase II Approval for PAD in China
2011-03-18
ViroMed Announces Final Patient Enrollment for US VM202-DPN Clinical Trial
2011-02-25
ViroMed and Enlyton Sign Licensing Agreement to Develop Humanized Antibody to TAG-72 for Cancer Detection
2010-04-27
ViroMed Submits Phase III Trial Application of VM501 for Chemotherapy-Induced Thrombocytopenia in China
2010-04-12
ViroMed’s DNA Medicine Receives Phase II Approval for PAD in Korea
11 12 13 14 15 16 17 18 19 20